Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Heini Lassus
Institutions:
University of Helsinki,
Helsinki University Hospital,
Nordic Society of Gynecologic Oncology,
Hospital District of Helsinki and Uusimaa
Observed institutions:
University of Helsinki,
Helsinki University Hospital,
Nordic Society of Gynecologic Oncology,
Hospital District of Helsinki and Uusimaa
OpenAlex ID:
A5159529293
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
2026
·
Domenica Lorusso
, Jérôme Martin-Babau
, et al.
·
The Lancet
·
3
Length of Ischemic Time Is Critical for Accurate Determination of Homologous Recombination Capacity by Immunofluorescence Staining in Ovarian Cancer Formalin-Fixed Paraffin-Embedded Samples
2026
·
Ezgi Karagöz
, Sanna Pikkusaari
, et al.
·
Archives of Pathology & Laboratory Medicine
·
1
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
2026
·
Brian M Slomovitz
, Jianqing Zhu
, et al.
·
The Lancet
·
1
Show more works
View as search
Works count:
3
Citation count:
5
H-index:
1
I10-index:
Year
Topic
Type